The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
It is intended for contrast enhancement in MRI scans
A triple-action Formula for comprehensive respiratory relief
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis
Standalone profit from operations for Q4-2024 were Rs. 108 crore
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Subscribe To Our Newsletter & Stay Updated
